. 2017 Aug 9;8(45):79854–79863. doi: 10.18632/oncotarget.20078

Table 3. The subgroup meta-analysis on survival outcome of OR following treatment with surgery or external beam radiotherapy.

OR	Factors	Overall survival (OS)			Cancer-specific survival (CSS)			Biochemical disease-free survival (BDFS)
OR	Factors	Studies size	OR (95% CI, p value)	I²	Studies size	OR (95% CI, p value)	I²	Studies size	OR (95% CI, p value)	I²
2-yr	All studies	5	1.56 (1.13–2.17, p = 0.008)	41%	6	1.27 (0.70–2.31, P = 0.42)	0%	6	0.21 (0.13–0.35, p < 0.00001)	65%
	Low risk	2	6.04 (0.99–36.78, p = 0.05)	0%	0	All no death	-	5	0.31 (0.14–0.71, p = 0.006)	0%
	Intermediate risk	2	1.93 (0.43–8.64, p = 0.39)	0%	1	3.35 (0.30–37.41, P = 0.33)	-	5	0.25 (0.09–0.66, p = 0.005)	54%
	High risk	2	2.19 (0.67–7.16, p = 0.19)	0%	3	1.55 (0.54–4.44, P = 0.42)	0%	5	0.16 (0.07–0.36, p < 0.0001)	77%
5-yr	All studies	5	3.18 (1.89–5.36, p < 0.0001)	77%	6	1.96 (1.42–2.72, P < 0.0001)	0%	7	0.42 (0.23–0.76, p = 0.004)	88%
	Low risk	3	3.48 (1.63–7.44, p = 0.001)	38%	1	4.95 (0.30–80.82, P = 0.26)	-	5	0.35 (0.07–1.69, p = 0.19)	77%
	Intermediate risk	3	4.67 (2.51–8.71, p < 0.00001)	0%	2	4.52 (0.68–30.15, p = 0.12)	0%	5	0.46 (0.22–0.94, p = 0.03)	71%
	High risk	3	2.90 (1.73–4.87, p < 0.0001)	0%	3	1.55 (0.76–3.17, p = 0.23)	0%	5	0.26 (0.13–0.55, p = 0.0004)	83%
10-yr	All studies	4	2.55 (1.63–3.99, p < 0.0001)	85%	6	2.44 (1.33–4.48, p = 0.004)	84%	-	-	-
	Low risk	1	2.49 (0.84–7.42, p = 0.10)	-	1	0.80 (0.09–6.86, p = 0.84)	-	-	-	-
	Intermediate risk	1	2.35 (1.18–4.66, p = 0.01)	-	1	9.28 (2.04–42.28, p = 0.004)	-	-	-	-
	High risk	1	2.92 (1.60–5.35, p = 0.0005)	-	2	2.11 (0.71–6.30, p = 0.18)	70%	-	-	-